Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
- Author:
Li BIN-BIN
1
;
Wang BO
;
Zhu CHENG-MING
;
Tang DI
;
Pang JUN
;
Zhao JING
;
Sun CHUN-HUI
;
Qiu MIAO-JUAN
;
Qian ZHI-RONG
Author Information
1. School of Biological Sciences,Nanyang Technological University,Singapore 639798,Singapore;Scientific Research Center,The Seventh Affiliated Hospital,Sun Yat-sen University,Shenzhen,Guangdong 518107,China
- Publication Type:Journal Article
- Keywords:
THZ1;
Cyclin-dependent kinase 7;
Cancer therapy;
Transcription;
Super-enhancer
- From:
Chronic Diseases and Translational Medicine
2019;5(3):155-169
- CountryChina
- Language:English
-
Abstract:
Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understanding with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which demonstrated promising anti-tumor activity against different cancer types. By introducing the anti-tumor behaviors and the po-tential targets for different cancers, this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms.
